Sharper blood test could uncover hidden cause of high blood pressure
NCT ID NCT07691801
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests whether a more precise lab technique (mass spectrometry) can improve the captopril test used to diagnose primary aldosteronism, a common but treatable cause of high blood pressure. Researchers will measure aldosterone and renin levels in blood samples from healthy volunteers and patients suspected of having the condition. The goal is to establish a new diagnostic cutoff that helps doctors identify this curable form of hypertension more accurately.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- captopril
- What this could lead to
- If successful, this could lead to a more accurate diagnostic test for primary aldosteronism, helping doctors identify a treatable cause of high blood pressure earlier.
- What could go wrong
- This is a diagnostic study, not a treatment trial. The new cutoff value may not prove significantly better than current methods, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 800 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
1)Healthy Controls to establish physiological suppression limits.2) Patients with suspected PA undergo captopril inhibition test to determine the cut-off point.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Normal Control Group Inclusion Criteria * Age 18-70 years old * BMI: 18.5-23.9kg/m² * Gender not restricted * Blood pressure: 100-120/60-80mmHg * No history of hypertension * No abnormal nodules found in adrenal CT * Previous blood potassium and electrocardiogram were all within normal ranges * No history of liver or kidney dysfunction, malignant tumors, metabolic diseases or cardiovascular diseases * No medication used Exclusion Criteria * Those with a family history of hypertension or with clinical manifestations of secondary hypertension * Those who have been taking drugs that may affect the RAAS system for a long time (such as contraceptives, steroids, etc.) * Those with cardiac dysfunction or severe arrhythmia and unable to tolerate the test Patients with suspected primary aldosteronism Inclusion Criteria: * Patients with suspected primary aldosteronism in the outpatient setting * Willing to undergo 4-week spironolactone treatment and cooperate with follow-up Exclusion Criteria: * Patients who did not complete the captopril suppression test * Patients with Cushing's syndrome or other endocrine tumors * Patients allergic to spironolactone or with contraindications for its use (such as severe hyperkalemia, eGFR \< 30) * History of liver or kidney dysfunction * Coexisting severe cardiovascular or cerebrovascular diseases * History of malignant tumors * Other types of endocrine hypertension (hyperthyroidism, pheochromocytoma, Cushing's syndrome, etc.) * Renal artery stenosis * Hypokalemia caused by other factors (renal tubular acidosis, Bartter syndrome, Gitelman syndrome, etc.) * Diabetes with HbA1c \> 7.0% or currently using or having used insulin or SGLT2 inhibitor drugs * Taking special medications such as glucocorticoids, immunosuppressants, oral contraceptives, etc
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary aldosteronism are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Peking Union Medical Colledge Hospital
RECRUITINGBeijing, Beijing Municipality, 456350, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill quiet the adrenal Glands' hormone overdrive?
- Sauna bathing may offer a sweat-based path to lower blood pressure
- Can a new PET scan light up hidden adrenal tumors causing high blood pressure?
- Wearable tech puts hormone health to the test
- New scan could replace risky vein test for Hormone-Driven high blood pressure
- New screening strategy could speed diagnosis of inherited aldosteronism